MedTrace Logo

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

NCT03379493 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2019-02-04

No results posted yet for this study

Summary

This is a non-randomized, single arm, open-label, single institution, phase I study to determine the maximum tolerated dose (MTD) of ET190L1 ARTEMIS™ T cells in patients ≥ 18 years of age with relapsed or refractory CD19+ Non-Hodgkin's lymphoma.

Conditions

  • Lymphomas Non-Hodgkin's B-Cell

Interventions

BIOLOGICAL

ET190L1 ARTEMIS™ T cells

Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • Duke Clinical Research Institute

    collaborator OTHER

  • Eureka Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • David A Rizzieri, MD · Duke University

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-04
Primary Completion
2018-12-23
Completion
2019-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03379493 on ClinicalTrials.gov